Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
From Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
From Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Which U.S. region saw the most fentanyl pill seizures in 2023?
Quiz
Which US region saw the most fentanyl pill seizures in 2023?
01/15/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
01/15/2025
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Expert Insights Quiz
Resources for Telehealth Rules and Regulations
01/06/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/06/2025
Psych Congress Network
How long does worry need to be present in order to diagnose GAD?
Quiz
How long does worry need to be present in order to diagnose GAD?
01/03/2025
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
01/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Antidepressant Discontinuation Symptoms
12/23/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/23/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Prodromal Symptoms in Schizophrenia
12/18/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/18/2024
Psych Congress Network
Are men or women more affected by depressive episodes?
Quiz
Are men or women more affected by depressive episodes?
12/17/2024
Pop quiz!
Pop quiz!
Pop quiz!
12/17/2024
Psych Congress Network
After how many months is 'problematic' opioid use diagnosed as OUD?
Quiz
After how many months is 'problematic' opioid use diagnosed as OUD?
12/16/2024
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
12/16/2024
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
12/11/2024
Psych Congress Network

Insights

marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Improving Cognition in Patients With Alzheimer’s Disease
Videos
Improving Cognition in Patients With Alzheimer’s Disease
11/11/2020
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric...
11/11/2020
Psych Congress Network
psych congress family and friends podcast
Podcasts
A New Beginning, and a Fond Farewell
01/06/2025
Join Dr Rakesh Jain and Dr Craig Chepke for an insightful and heartfelt conversation in the inaugural Psych Congress Family & Friends Podcast. A discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an...
Join Dr Rakesh Jain and Dr Craig Chepke for an insightful and heartfelt conversation in the inaugural Psych Congress Family & Friends Podcast. A discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an...
Join Dr Rakesh Jain and Dr Craig...
01/06/2025
Psych Congress Network
psych congress family and friends podcast
Podcasts
Welcome to Psych Congress Family & Friends Hosted by Rakesh Jain and Craig Chepke
01/06/2025
Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!
Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!
Introducing our new psychiatry...
01/06/2025
Psych Congress Network
Brooke Kempf
Videos
Addressing Misconceptions About LAI Antipsychotics
01/06/2025
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of...
01/06/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
How to Navigate Insurance When Treating Tardive Dyskinesia
01/06/2025
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews,...
01/06/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
How to Navigate Insurance When Treating Tardive Dyskinesia
01/06/2025
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews,...
01/06/2025
Psych Congress Network
Andrew Penn, PMHNP-BC
Videos
Best Practices for Deprescribing in Schizophrenia
12/05/2024
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn,...
12/05/2024
Psych Congress Network
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych
Videos
Understanding Antipsychotic-Induced Movement Disorders
12/05/2024
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C,...
12/05/2024
Psych Congress Network
Edward Kaftarian, MD.
Videos
How to Maintain Up-To-Date Telehealth Regulation Compliance
12/03/2024
Edward Kaftarian, MD, offers some practical tips for maintaining regulatory compliance while managing a busy telehealth practice.
Edward Kaftarian, MD, offers some practical tips for maintaining regulatory compliance while managing a busy telehealth practice.
Edward Kaftarian, MD, offers...
12/03/2024
Psych Congress Network
Dr Craig Chepke
Schizophrenia Conference Insights
Muscarinic Acetylcholine Receptors in Schizophrenia: A Shift From Dopamine D2 to Muscarinic Agonists
11/27/2024
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
In this video, Craig Chepke, MD,...
11/27/2024
Psych Congress Network

Practice Tools

US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
FDA Approves Donanemab for Early Alzheimer Disease Treatment
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
A teddy bear against a blue background wearing a mask and stethoscope.
News
Prenatal Glucocorticoid Exposure Linked With Increased Mental Disorder Risk
01/17/2025
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to...
01/17/2025
Psych Congress Network
A child sleeps in bed on her stomach with her mouth hanging open
News
Loudness of Snoring May Indicate Greater Hyperactivity in Children and Adolescents
01/16/2025
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless...
01/16/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Which U.S. region saw the most fentanyl pill seizures in 2023?
Quiz
Which US region saw the most fentanyl pill seizures in 2023?
01/15/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
01/15/2025
Psych Congress Network
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
News
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
01/14/2025
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression...
01/14/2025
Psych Congress Network
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
News
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
01/14/2025
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses...
01/14/2025
Psych Congress Network
News
Meta-Analysis Finds Little Support for Neurofeedback for ADHD
01/13/2025
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show...
01/13/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
News
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
01/08/2025
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with...
01/08/2025
Psych Congress Network

News Articles

US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
Obstructive Sleep Apnea Events During REM Sleep Impacts Verbal Memory in Those at Risk for AD
05/20/2024
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
Prenatal Glucocorticoid Exposure Linked With Increased Mental Disorder Risk
01/17/2025
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to...
01/17/2025
Psych Congress Network
A child sleeps in bed on her stomach with her mouth hanging open
News
Loudness of Snoring May Indicate Greater Hyperactivity in Children and Adolescents
01/16/2025
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless...
01/16/2025
Psych Congress Network
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
News
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
01/14/2025
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression...
01/14/2025
Psych Congress Network
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
News
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
01/14/2025
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses...
01/14/2025
Psych Congress Network
News
Meta-Analysis Finds Little Support for Neurofeedback for ADHD
01/13/2025
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show...
01/13/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
News
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
01/08/2025
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with...
01/08/2025
Psych Congress Network
Methylphenidate or Atomoxetine Maintenance Safe During Pregnancy
News
Methylphenidate or Atomoxetine Maintenance Safe During Pregnancy
01/08/2025
Maintenance of methylphenidate or atomoxetine may be safe during pregnancy, according to recent systematic review and meta-analysis results published in JAMA Network Open. 
Maintenance of methylphenidate or atomoxetine may be safe during pregnancy, according to recent systematic review and meta-analysis results published in JAMA Network Open. 
Maintenance of methylphenidate...
01/08/2025
Psych Congress Network
brain waves schizophrenia transcranial magnetic stimulation
News
Review Questions Utility of tDCS for Cognitive Symptoms in Schizophrenia
01/08/2025
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions...
01/08/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network

Posters

Real-world clinical effectiveness of esketamine nasal spray based on the Montgomery-Asberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in the United States
BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...
11/26/2024
Response and remission on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
11/26/2024
Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation
BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...
11/26/2024
Effect of Centanafadine on AISRS Over 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials
TBD
11/26/2024
Impact of Centanafadine on the ASRS After 6 Weeks of Treatment of ADHD in Adults: A Pooled Analysis of Two Phase 3 Trials
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
11/26/2024
Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
11/26/2024
Guiding antidepressant choice by applying deep learning approaches on individual patient-derived neurons: a window to drug efficacy in each patient
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
11/26/2024
Clinical effectiveness and persistence on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
11/26/2024
Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
Background: This study evaluated the dose-response relationship of efficacy, safety, and tolerability for single-dose MM120 (lysergide D-tartrate) vs placebo in participants with generali...
11/26/2024
Hyperprolactinemia In The Setting Of Risperidone Use and Delusions of Pregnancy
Risperidone, an atypical antipsychotic, is known to be the most likely of its class of medication to cause hyperprolactinemia. We present a case of a 33 year old female with no known psyc...
11/26/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use